In a landmark move that signals a significant shift in pharmaceutical investment, Eli Lilly and Company has announced the acquisition…
Read More
Lilly offers up to $3.8 billion for AtaiBeckley in bet on ‘God molecule’ found in toad venom
Eli Lilly has formally agreed to acquire AtaiBeckley for a substantial sum, comprising $2.8 billion upfront and an additional $1…
Read More
Biogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion Acquisition
Three months after Biogen finalized its substantial $5.6 billion acquisition of Apellis Pharmaceuticals, a significant shift in research and development…
Read More
Ionis Forecasts $2 Billion Peak Sales for Tryngolza, Leveraging First-Mover Advantage in Severe Hypertriglyceridemia
Ionis Pharmaceuticals is poised to redefine its market position with ambitious peak sales forecasts of $2 billion for its newly…
Read More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Bolster Immunology Pipeline
AbbVie has announced a landmark $10.9 billion acquisition of Apogee Therapeutics, a strategic move poised to significantly fortify the biopharmaceutical…
Read More
Biogen Acquires RayThera for Up to $1 Billion to Bolster Immunology Pipeline
Biogen Inc. has announced a definitive agreement to acquire RayThera, a privately held biotechnology company focused on developing small-molecule therapies…
Read More
Biopharma M&A Surges as Billion-Dollar Deals Fuel Pipeline Replenishment Amidst Patent Cliff Pressures
The biopharmaceutical industry is experiencing a significant resurgence in merger and acquisition (M&A) activity, driven by a wave of high-value…
Read More
Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’
A transformative partnership has been forged between Insilico Medicine, a pioneer in artificial intelligence-driven drug discovery, and Eli Lilly, a…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company is embarking on a significant acquisition spree, exemplified by its recent agreement to acquire Kelonia Therapeutics…
Read More
Eli Lilly and Company Secures Global Rights to Hanmi Pharm’s Sonefpeglutide in Potential $1.26 Billion Deal
Eli Lilly and Company has forged a significant licensing agreement with South Korean biopharmaceutical firm Hanmi Pharm, potentially worth up…
Read More
